Genetic Manipulation and Selection of Mouse Mesenchymal Stem Cells for Delivery of Therapeutic Factors In Vivo.
Genetic Manipulation and Selection of Mouse Mesenchymal Stem Cells for Delivery of Therapeutic Factors In Vivo. Methods Mol Biol. 2019;1940:143-155 Authors: Sakaguchi DS Abstract Bone marrow-derived mesenchymal stem cells (MSCs) hold great potential as an ex vivo cellular system for delivery of therapeutic proteins to the diseased or damaged central nervous system (CNS). This adult stem cell population has considerable translational potential for autologous transplantation due to lack of ethical concerns, accessibility, multipotent nature, and plasticity. Here we describe a methodology and outline a strategy using lentiviral vectors for producing lines of MSCs hypersecreting neurotrophic growth factors (e.g., brain-derived neurotrophic factor (BDNF) and/or glial cell line-derived neurotrophic factor (GDNF)) together with a reporter protein such as green fluorescent protein (GFP) that may be used for in vitro and in vivo neuroprotection bioassays. This approach provides exciting opportunities for basic research and proof-of-concept studies. PMID: 30788823 [PubMed - indexed for MEDLINE]
Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ram Vasudevan Nampoothiri, Shiyi Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Fotios V. Michelis, Dennis Dong Hwan Kim, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson, Arjun Datt Law
ConclusionSOS is relatively rare; therefore, a holistic approach to the patients ’ needs considering nursing role as essential may result in better care outcomes.
Publication date: December 2020Source: Journal of Chemical Neuroanatomy, Volume 110Author(s): Maryam Sadat Jalali, Alireza Sarkaki, Yaghoub Farbood, Seyed saeed Azandeh, Esrafil Mansouri, Mohammad Ghasemi Dehcheshmeh, Ghasem Saki
We report a rare case of HBV reactivation in a patient with HCV infection after DAA therapy. Patient concerns: In 1996, a 53-year-old female was identified as infected with HCV at a medical check-up, following which she visited our hospital. She was infected with HCV genotype 2b, and at follow up in 1997, was found to be hepatitis B surface antigen (HBsAg) and antibody against HBsAg negative, antibody against HBV core positive. She then experienced malignant lymphoma in 2001 at 58 years of age. Complete remission was achieved following chemotherapy and autologous peripheral blood stem cell transplantation. In 2014, she ...
BONE MARROW TRANSPLANTATION (BMT) also called haematopoietic stem cell transplant (HSCT) is the treatment of choice for many haematological diseases including haematological malignancies and different types of anaemia1. The number of HSCT is increasing every year, mainly because of advanced research that has allowed an expansion in the number of indications for which it has become the first-line therapy2. The long-term survival of patients that have undergone BMT continues to improve with several advances in transplantation techniques and supportive care practices.
Chronic graft-versus-host disease (cGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation that affects various organs leading to a reduced quality of life. The condition often requires enduring immunosuppressive therapy, which can also lead to the development of severe side effects. Several approaches including small molecule inhibitors, antibodies, cytokines, and cellular therapies are now being developed for the treatment of cGvHD, and some of these therapies have been or are currently tested in clinical trials. In this review, we discuss these emerging therapies with particular emphasis on...
Epstein –Barr virus (EBV) is associated with the pathogenesis of a variety of malignancies, most notably lymphomas. Especially in the background of immunodeficiency, such as primary immunodeficiency disorder (P...
ConclusionIn this review, we attempted to provide a historical overview of bone marrow history, MSC discovery, characterization, and the first clinical studies conducted.
Conclusion: Our results suggest that children who develop ARF during engraftment have better ICU survival rates than do those with other etiologies of ARF post-HSCT. Furthermore, fluid overload contributes to mortality in these children; therefore, strategies to prevent and address fluid overload should be considered.
Condition: Hematopoietic Stem Cell Transplantation Intervention: Procedure: Hematopoietic stem cell transplantation Sponsor: IRCCS Burlo Garofolo Completed